English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.38 |
| Open | 0.39 |
| 1-Year Change | -2.5% |
| Day's Range | 0.39 - 0.4 |
Tonix Pharmaceuticals Holding Corp. (TNXP) is a clinical-stage biopharmaceutical company that focuses on understanding diseases and developing innovative therapies with the potential to address unmet needs.
Headquartered in Chatham, New Jersey, Tonix Pharma was founded in 2007 with the idea of developing a diverse yet curated portfolio of small molecule drugs across various therapeutic areas, like the central nervous system (CNS), immunology, infectious disease and rare diseases. With a significant investment in in-house research and development and manufacturing, Tonix Pharma accelerates the drug development and reachability timeline and can respond immediately in case of an infectious disease breakout.
The company’s CNS portfolio comprises TNX-102 SL (Confirmatory Phase 3) for Fibromyalgia. Drugs in phase 2 development are TNX-102 SL for Posttraumatic Stress Disorder (PTSD), TNX-102 SL for long Covid, TNX-1300 for cocaine overdose and TNX-1900 for chronic migraine. It also has two drugs in the preclinical phase: TNX-1500 for organ transplant rejection/autoimmune disorders and TNX-1700 for gastric and colorectal cancers.
Pathogenic infections like smallpox and monkeypox have been a core area of focus for Tonix for a long time, however, the Covid-19 outbreak pushed the company to focus on rapid preparedness to combat infectious diseases. The company has the TNX-1840/1850 Covid-19 vaccine, TNX-3500 Covid-19 antiviral, TNX-3600 Covid-19 therapeutic and TNX-801 smallpox and monkeypox vaccine under development and in preclinical stages.
Tonix’s rare disease portfolio includes TNX-2900 for Prader-Willi syndrome, which is in the preclinical stage.
Tonix shares began trading under the ticker symbol ‘TNXP’ on the Nasdaq Capital Market in August 2013.
